Sensex Today | Stock Market Live Updates: Sensex , Nifty Slip as Oil Shock Fears Rise; Rupee Sinks to Fresh Low

Why It Matters

The mixed sector performance highlights volatility from oil‑price fears, while ACUTAAS’s multi‑engine growth model could draw capital to India’s high‑margin specialty chemicals space and pharma stocks like Laurus Labs may ride strong earnings momentum.

Key Takeaways

• Nifty 50 closed +0.5% below 24,120 level.
• Pharma index up 0.9%; Laurus Labs tops gains.
• ACUTAAS completed 2,000‑MT battery chemicals Phase 1.
• FY27 revenue growth target ~25% with 35% EBITDA margin.
• ACUTAAS FY27 capex ₹90 Cr (~$11 M) for expansion.

Pulse Analysis

The Indian equity market ended Monday on a modest rally, with the Nifty 50 edging up 0.5% to just under 24,120 and the Sensex mirroring the gain. The advance came despite heightened oil‑price anxiety that pushed the rupee to a fresh low against the dollar, underscoring the market’s resilience to macro‑headwinds. Pharma led the charge, adding 0.9%, while information‑technology slipped 0.9%, reflecting divergent earnings expectations. Heavyweights such as Adani Ports and Jio Financial posted the strongest gains, whereas Bharti Airtel and Kotak Mahindra Bank lagged.

Within the pharma segment, Laurus Labs stood out, trading around ₹1,166.50 with support near ₹1,090 and upside projected to ₹1,300. The stock’s momentum is buoyed by robust pipeline progress and a favorable regulatory environment, making it a focal point for investors seeking exposure to India’s growing generic‑drug market. The broader pharma index’s 0.9% rise signals renewed confidence in sector earnings, especially as domestic demand for affordable medicines accelerates and export opportunities expand.

ACUTAAS Chemicals used the update to highlight a multi‑engine growth strategy anchored by battery‑chemical production and contract‑development‑and‑manufacturing‑organisation (CDMO) services. Phase 1 of its Jhagadia plant, delivering 2,000 MT of VC and FEC, is now operational, and a second phase is slated for Q1 FY27. Management projects FY27 revenue to climb roughly 25% with EBITDA margins hovering around 35%, supported by a ₹90 Cr (≈$11 million) capex plan that funds capacity expansion and R&D. The company’s diversified product roadmap and long‑term supply contracts position it to capture rising demand in electric‑vehicle batteries and specialty pharma, offering investors a high‑margin, growth‑oriented play.